



Metabolic Soft Spot

Introduction


The concept of "soft" drugs involves the controlled degradation of substances to treat acute conditions that require a rapid onset and temporary action.¹ Recently, researchers at Bayer AG developed a dual factor IIa/Xa inhibitor featuring an ester bond as a soft spot for the clearance of the substance from plasma through ester bond hydrolysis. These esters, based on the molecular structure of diaminopropionic acid, demonstrated a half-life of 0.2-0.3 hours *in vivo*, supporting the advancement of the optimized molecule (BAY 3389934) to clinical trials.² Explore our collection of diaminopropionic acid derivatives to construct your molecules!



Case study



We offer: over 100 compounds based on diaminopropionic acid skeleton from stock on 5-10 gram scale.



References

1. P. Buchwald. *Expert Opin. Drug Metab. Toxicol.* **2020**, *16*, 645.
2. H. Beck et al. *J. Med. Chem.* **2025**, *68*, 12687.



Search & Buy on-line at **EnamineStore.com**
Look for more at Chem-Space.com

BB@enamine.net, www.enamine.net

